Valuation: HLS Therapeutics Inc.

Market Cap 90.43M 78.22M 73.05M 67.01M 126M 8.61B 128M 857M 336M 4.31B 340M 332M 14.26B P/E 2026 *
-14.5x
P/E 2027 * -96.4x
Enterprise Value 90.43M 78.22M 73.05M 67.01M 126M 8.61B 128M 857M 336M 4.31B 340M 332M 14.26B EV / Sales 2026 *
1.56x
EV / Sales 2027 * 1.41x
Free-Float
99.47%
Yield 2026 *
-
Yield 2027 * -
1 day-3.25%
1 month-0.67%
3 months-12.92%
6 months-11.36%
Current year-13.12%
1 month 2.98
Extreme 2.98
3.08
Current year 2.98
Extreme 2.98
3.44
1 year 2.98
Extreme 2.98
4.02
3 years 2.22
Extreme 2.22
4.02
5 years 2.22
Extreme 2.22
16.44
10 years 0
Extreme 0
19.1
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2023
Director of Finance/CFO 61 26/01/2024
Chief Tech/Sci/R&D Officer 61 01/06/2014
Director TitleAgeSince
Director/Board Member 58 12/03/2018
Chairman 48 22/06/2023
Director/Board Member 65 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-3.25%-.--% - - 90.43M
+2.50%+7.88%+32.64%+105.61% 101B
+0.47%+0.79%+50.62%+157.17% 55.37B
-0.67%+0.68%+3.50%+274.68% 24.21B
+1.64%-0.95%-12.47%-14.01% 8.29B
+2.21%+1.79%-30.23%-26.46% 7.53B
+0.59%-1.84%-9.64%-21.74% 6.75B
+0.22%+3.37%+19.42%+15.32% 6.19B
+0.12%-2.84%-4.09%+21.34% 5.07B
+0.81%-3.11%-6.73%-7.85% 3.69B
Average +0.46%-0.07%+4.78%+56.01% 24.28B
Weighted average by Cap. +1.38%+1.47%+26.89%+117.96%

Financials

2026 *2027 *
Net sales 58.03M 50.2M 46.88M 43M 80.88M 5.52B 82.16M 550M 216M 2.77B 218M 213M 9.15B 64.31M 55.63M 51.95M 47.66M 89.64M 6.12B 91.06M 610M 239M 3.07B 242M 236M 10.14B
Net income -6.26M -5.42M -5.06M -4.64M -8.73M -596M -8.87M -59.37M -23.3M -299M -23.52M -23.01M -988M -1.05M -908K -848K -778K -1.46M -99.93M -1.49M -9.95M -3.91M -50.09M -3.94M -3.86M -166M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.891USD
Average target price
5.179USD
Spread / Average Target
+79.11%

Quarterly revenue - Rate of surprise